Cincinnati Eye Institute

LONDON, UK and CAMBRIDGE, MA, USA I October 15, 2024 I Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading ophthalmic gene therapy company with a purpose to save and restore the vision of patients with blinding retinal diseases, today announced the presentation of 24-month interim safety and efficacy results of the Phase 2 SKYLINE trial in patients with XLRP at the American Academy of Ophthalmology’s Annual Meeting in Chicago, Illinois. The 24-month data showed a response rate of 57% (4/7) in study eyes treated with a high dose (6.8 E+11 vg/eye) of AGTC-501, defined as a patient who has an improvement in retinal sensitivity as assessed by microperimetry of at least 7 decibels (dB) in at least 5 loci. Patients in the high-dose cohort also showed a robust improvement in mean retinal sensitivity. Study eyes treated with a low dose (7.5 E+10 vg/eye) of AGTC-501 showed a response rate of 25% (1/4). There were no clinically significant safety events associated with AGTC-501 treatment in this trial, and any treatment-emergent adverse events were mostly non-serious and mild to moderate in severity. XLRP is a severe, aggressive, inherited retinal disease that often leads to blindness by middle age, with no treatment options available. XLRP primarily affects an estimated 3.4 – 4.4 per 100,000 young males with RPGR mutations in US, Europe and Australia. AGTC-501 expresses the full length RPGR protein and is therefore expected to address the entirety of photoreceptor damage caused by XLRP, including both rod and cone loss, making it uniquely well-suited to improve the lives of patients with XLRP as a potential treatment. Lance Baldo, MD, Chief Executive Officer of Beacon Therapeutics, stated, “Our Phase 2 SKYLINE 24-month data reinforces AGTC-501’s favorable safety profile and robust improvements in mean retinal sensitivity. We will continue to assess the long-term safety and durability of AGTC-501 but are encouraged by the results we’ve seen in the SKYLINE trial to date.” Beacon Therapeutics is also enrolling its pivotal Phase 2/3 VISTA and open-label Phase 2 DAWN trials as the Company progresses toward the development of a treatment for XLRP. Poster – Subretinal AGTC-501 Gene Therapy for XLRP: 24-Month Interim Results of the Phase 2 SKYLINE Trial. Presenting Author – Robert Sisk, MD, FACS, FASRS, Associate Professor of Ophthalmology at the University of Cincinnati; Vitreoretinal Surgeon and partner at Cincinnati Eye Institute; Director of Pediatric Retinal Surgery and Director of Ophthalmic Genetics at Cincinnati Children’s Hospital. Contact: info@beacontx.com Media: beacontherapeutics@edelman.com About Beacon Therapeutics Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP), as well as two preclinical programs, one targeting dry age-related macular degeneration (AMD) and another targeting an inherited cone-rod dystrophy (CRD). Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space. Lead development candidate AGTC-501, is a gene therapy program currently being investigated for the treatment of XLRP, an inherited monogenic recessive disorder that causes progressive vision loss, primarily in boys and young men. XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. AGTC-501 expresses the full length RPGR protein, thereby addressing the full complement of photoreceptor damage caused by XLRP, including both rod and cone loss. Beacon is supported by funds from Syncona Limited, Forbion, Oxford Science Enterprises, TCGX, Advent Life Sciences and additional investors. Find out more about Beacon Therapeutics at beacontx.com. SOURCE: Beacon Therapeutics Holdings

CINCINNATI--( BUSINESS WIRE )--EyeCare Partners (ECP), the nation’s leading provider of clinically integrated eye care, today announced the grand opening of its Cincinnati Eye Institute (CEI) Retina Clinic at The Landings in Blue Ash, furthering its commitment to providing the highest quality eye care. Located at 9997 Carver Road, Level 2, in Blue Ash, this new state-of-the-art 36,000-square-foot clinical space is CEI’s 16 th office in the greater Cincinnati area. “ As demand for quality eye care continues to rise, we at CEI are ready to meet this challenge through growth and expansion, so our greater Cincinnati area patients continue to enjoy access to world-class eye services right in their own backyard,” said James Osher, M.D., a third-generation Cincinnati ophthalmologist and Ohio Division Medical Director for EyeCare Partners. “ What makes this office so special is its singular focus on medical and surgical treatment of the retina,” added Osher. “ The office is unique with state-of-the-art retina equipment, including the most advanced retina imaging platforms available. We will also be able to expand our bustling clinical trial and research services. This allows more patients the opportunity to participate in cutting-edge therapies.” The new CEI Retina Clinic supports the expansion of CEI’s clinical trial capabilities, allowing patients access to investigational medical and surgical care. Currently, CEI has 28 active retina clinical trials. “ At CEI, we are focused on enhancing vision, advancing eye care and improving lives. The new CEI Retina Clinic advances our mission with world-class specialists working with the latest technology in a patient-friendly space,” said Daniel M. Miller, M.D., Ph.D., Ophthalmology Division President and Executive Medical Officer, EyeCare Partners. “ CEI is also pioneering the future of eye care through our robust clinical trial programs in the Cincinnati area, and this space will help advance the future of retina care broadly.” About Retinal Diseases Retinal diseases currently impact more than 10 million Americans. These diseases affect the retina, the light-sensitive tissue located in the back of the eye. Common retinal diseases include diabetic retinopathy, macular degeneration, retinal tears and detachments, macular holes and retinitis pigmentosa. Retinal diseases can cause symptoms that impact vision, such as blindness or low vision. The most common causes of retinal damage include genetic and environmental factors, and these can be related to old age, light damage or trauma. About EyeCare Partners EyeCare Partners is the nation’s leading provider of clinically integrated eye care. Our national network of over 300 ophthalmologists and 700 optometrists provides a lifetime of care to our patients with a mission to enhance vision, advance eye care and improve lives. Based in St. Louis, Missouri, over 700 ECP-affiliated practice locations provide services that span the eye care continuum in 18 states and 30 markets. For more information, visit www.eyecare-partners.com , and follow us on LinkedIn .

ST. LOUIS--(BUSINESS WIRE)-- EyeCare Partners (ECP), the nation’s leading provider of clinically integrated eye care, today announced more than 20 of its physicians will be presenting the latest innovative modalities and mechanisms across a wide range of ophthalmic disciplines in 90 sessions at the American Society of Cataract and Refractive Surgery (ASCRS). The annual meeting will take place May 5-8, 2023, in San Diego. The breadth of topics being presented at ASCRS by ECP physicians emphasizes the company’s culture of innovation and continuous learning. It also underscores the possibility of a career “third pathway” which allows physicians to conduct industry-leading research while also continuing to build a clinical practice. “EyeCare Partners has a strong representation of ophthalmologists presenting research at ASCRS this year, in addition to one of our specialists, Dr. Elizabeth Yeu, serving as the incoming president of ASCRS,” said David Clark, CEO of EyeCare Partners. “We are committed to elevating eye care, and we are proud to work with many ophthalmologists who are leading educators in their field and committed to advancing eye care through innovation and clinical research.” Select ECP physician presentations at ASCRS include: “Prospective Evaluation of Eye Drop Self-Administration Accuracy in a Real-World Patient Population” – Alison Early, M.D., Cincinnati Eye Institute “Cardiovascular Effects of Immunosuppression for Ocular Surface Stem Cell Transplantation” – Albert Y. Cheung, M.D., Virginia Eye Consultants “Treatment of Corneal Neovascularization Prior to Deep Anterior Lamellar Keratoplasty” – Albert Cheung, M.D., Virginia Eye Consultants “Corneal Healing after Cenegermin Treatment in Patients with Stage 1 Neurotrophic Keratopathy” – Gregg Berdy M.D., Ophthalmology Associates “Cryopreserved Amniotic Membrane during Pterygium Excision: Health Economic Opportunity Analysis” – Neel Desai, M.D., Eye Institute of West Florida “Surgeon and Patient Experience Following Toric IOL Alignment with and without a Novel Ocular Registration-Guided Graphical Overlay System” – Robert Weinstock, M.D., Eye Institute of West Florida “Retrospective Assessment of the Routine Use of Loteprednol Etabonate Gel 0.38% Following LASIK and PRK Surgery” – Joseph Gira, M.D., Ophthalmology Associates “Interim Assessment of Safety & Efficacy of Human Corneal Endothelial Cell Therapy for Corneal Edema Secondary to Endothelial Dysfunction” – Edward Holland, M.D., Cincinnati Eye Institute “A Trifocal Lens with New Hydrophobic Acrylic Lens Material: A Study of Patient Satisfaction and Visual Performance” – Michael Jones, M.D., Quantum Vision Centers “EW-6 Be part of History in the making…The Big Bang in surgical visualization systems has arrived” – Caroline Watson, M.D., Alabama Vision Center, John Kitchens, M.D., Retina Associates of Kentucky “Axial Length Related Visual Outcomes in an Extended Depth of Focus Lens Implantation” – Rohit Krishna, M.D., Sabates Eye Centers “Sublingual Midazolam and Ketamine for Surgical Sedation, a Multicenter, Double Masked, Randomized Controlled Trial” – Michael Nordlund, M.D., Ph.D., Cincinnati Eye Institute “Visual Outcomes of the Tecnis Symfony Lens in Patients with Ocular Hypertension and Mild to Moderate Glaucoma” – Constance Okeke, M.D., Virginia Eye Consultants “IC-124 Management of Complications Encountered during Cataract Surgery” – Robert Osher, M.D., Cincinnati Eye Institute “STL-2 Iris Prothesis” – Samantha Schockman, M.D., Cincinnati Eye Institute “Real-World Outcomes of Intranasal Varenicline for the Treatment of Dry Eye Disease” – Amar Shah, M.D., Cincinnati Eye Institute “Sterile and Infectious Infiltrates after Epithelial Defect Treatment with Cryopreserved and Dehydrated Amniotic Membrane: A Case Series” – John D. Sheppard, M.D., Virginia Eye Consultants “Refractive impact of topical meds” – Kavitha Sivaraman, M.D., Cincinnati Eye Institute “IC-001 The Wonderful World of Iris Prostheses: A Case-Based Compendium” – Michael Snyder, M.D., Cincinnati Eye Institute “Eyeninja - Danger in the Dark: Introducing the Eidolon Handheld Slit Beam” – Lawrence Tenkman, M.D., John-Kenyon Eye Centers “Can't Touch That!” – Megan Tuohy, M.D., Cincinnati Eye Institute, Michael Snyder, M.D., Cincinnati Eye Institute “Effectiveness of Femtosecond Laser Assisted Cataract Surgery and Manual Phacoemulsification during the Learning Curve of Fellows in Training” – Robert Weinstock, M.D., Eye Institute of West Florida “Safety & Efficacy of Lotilaner Ophthalmic Solution, 0.25% in Treating Demodex Blepharitis: Combined Analysis of Two Pivotal Trials” – Elizabeth Yeu, M.D., Virginia Eye Consultants “CSF-1 (0.4% Pilocarpine HCl Ophthalmic Solution) for the Treatment of Presbyopia: Near-1 and Near-2 Phase 3 Clinical Trials” – Edward J. Holland, M.D., Cincinnati Eye Institute “Effects of Uncrosslinking Ocular Rigidity in Aging Eyes: Rejuvenation of Visual Age Utilizing a New Microporation Therapy” – Elizabeth Yeu, M.D., Virginia Eye Consultants “Prospective, Randomized, Contralateral Eye Study of Femtosecond Laser Assisted Cataract Surgery and Manual Phacoemulsification” – Robert Weinstock, M.D., Eye Institute of West Florida “Interim Assessment of Safety & Efficacy of Human Corneal Endothelial Cell Therapy for Corneal Edema Secondary to Endothelial Dysfunction” – Elizabeth Yeu, M.D., Virginia Eye Consultants “Efficiency of a water-free topical cyclosporine in the treatment of dry eye disease (DED) in patients with or without cataract” – John D. Sheppard, M.D., Virginia Eye Consultants “Changes in Creatinine Levels Related to Tacrolimus Used for Ocular Surface Stem Cell Transplantation” – Albert Y. Cheung, M.D., Virginia Eye Consultants About EyeCare Partners EyeCare Partners is the nation’s leading provider of clinically integrated eye care. Our national network of over 300 ophthalmologists and 700 optometrists provides a lifetime of care to our patients with a mission to enhance vision, advance eye care and improve lives. Based in St. Louis, Missouri, over 700 ECP-affiliated practice locations provide services that span the eye care continuum in 18 states and 30 markets. For more information, visit and follow us on LinkedIn.